Individuals who stop taking the popular new weight-loss drug tirzepatide, sold under the brand name Zepbound, are bound to regain some of their lost weight, according to results of a new trial study.
Zepbound is an injectable weight-loss drug that has gained popularity since the U.S. Food and Drug Administration (FDA) approved its use for chronic weight management in November 2023. It is injected once weekly with an increasing dose over four to 20 weeks with a target dosing size between 5 and 15 milligrams per week. The drug works similarly to other favored weight-loss drugs like Wegovy by managing glucose levels.
